Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Radka Obermannová, María Alsina, Andrés Cervantes, et al.
Annals of Oncology (2022) Vol. 33, Iss. 10, pp. 992-1004
Closed Access | Times Cited: 372

Showing 1-25 of 372 citing articles:

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Jianming Xu, Ken Kato, Eric Raymond, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 5, pp. 483-495
Closed Access | Times Cited: 143
How we treat esophageal squamous cell carcinoma
Hannah Christina Puhr, Gerald W. Prager, Aysegül Ilhan‐Mutlu
ESMO Open (2023) Vol. 8, Iss. 1, pp. 100789-100789
Open Access | Times Cited: 49
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato, et al.
BMJ (2024), pp. e078876-e078876
Open Access | Times Cited: 48
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial
Ken Kato, Ryunosuke Machida, Yoshinori Ito, et al.
The Lancet (2024) Vol. 404, Iss. 10447, pp. 55-66
Closed Access | Times Cited: 42
Advances in diagnosis and management of cancer of the esophagus
Nathaniel Deboever, Christopher M. Jones, Kohei Yamashita, et al.
BMJ (2024), pp. e074962-e074962
Open Access | Times Cited: 35
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
Jens Hoeppner, Thomas Brunner, Claudia Schmoor, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 4, pp. 323-335
Closed Access | Times Cited: 5
Unraveling the tumor microenvironment of esophageal squamous cell carcinoma through single-cell sequencing: A comprehensive review
Lingyu Qi, Jiaxin Wang, Shuang Hou, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189264-189264
Closed Access | Times Cited: 1
Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers
Zhihao Lu, Mingfei Geng, Yongtao Han, et al.
Cancer Biology and Medicine (2025) Vol. 21, Iss. 12, pp. 1171-1184
Open Access | Times Cited: 1
Improving outcomes in patients with oesophageal cancer
Manish A. Shah, Nasser K. Altorki, Pretish Patel, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 390-407
Closed Access | Times Cited: 37
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial
Qi Liu, Junqiang Chen, Lin Yu, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 9, Iss. 1, pp. 45-55
Closed Access | Times Cited: 32
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
Tiuri E. Kroese, Hanneke W.M. van Laarhoven, Sebastian F. Schoppman, et al.
European Journal of Cancer (2023) Vol. 185, pp. 28-39
Open Access | Times Cited: 31
Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer
Junyu Li, Lin Li, Peimeng You, et al.
Seminars in Cancer Biology (2023) Vol. 91, pp. 35-49
Closed Access | Times Cited: 28
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial
Klara Nilsson, Fredrik Klevebro, Berit Sunde, et al.
Annals of Oncology (2023) Vol. 34, Iss. 11, pp. 1015-1024
Open Access | Times Cited: 25
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
Jin Li, Zhendong Chen, Yuxian Bai, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 740-748
Open Access | Times Cited: 14
European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
Tiuri E. Kroese, Sebastiaan F. C. Bronzwaer, Peter S.N. van Rossum, et al.
European Journal of Cancer (2024) Vol. 204, pp. 114062-114062
Open Access | Times Cited: 13
Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings
Daniel Park, Won Jin Jeon, Chieh Yang, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 318-318
Open Access | Times Cited: 10
Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions
Jiaqi Liu, Lijun Dai, Qiang Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial
Ruinuo Jia, Tanyou Shan, Anping Zheng, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 20, pp. 2436-2445
Open Access | Times Cited: 8
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives
Yasushi Sato, Koichi Okamoto, Yutaka Kawano, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 14, pp. 4646-4646
Open Access | Times Cited: 19
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma
Massimiliano di Pietro, Nigel Trudgill, Melina Vasileiou, et al.
Gut (2024) Vol. 73, Iss. 6, pp. 897-909
Open Access | Times Cited: 7
Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus
Rainer Porschen, Wolfgang Fischbach, Ines Gockel, et al.
United European Gastroenterology Journal (2024) Vol. 12, Iss. 3, pp. 399-411
Open Access | Times Cited: 5
Impact of Metastatic Lymph Nodes on Survival of Patients with pN1-Category Esophageal Squamous Cell Carcinoma: A Long-Term Survival Analysis
Kexun Li, Kunyi Du, Changding Li, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 6, pp. 3794-3802
Open Access | Times Cited: 5
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023
Yuko Kitagawa, Satoru Matsuda, Takuji Gotoda, et al.
Gastric Cancer (2024) Vol. 27, Iss. 3, pp. 401-425
Open Access | Times Cited: 5
Esophageal cancer
Daniel C. Eisner
JAAPA (2024) Vol. 37, Iss. 4, pp. 19-24
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top